Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology · ATP13A2-Related Disorder

Living with ATP13A2 Disorders and Long-Term Outlook

At a Glance

ATP13A2-related CLN12 disease is progressive, but its pace and symptoms vary widely. Planning early for mobility, thinking and behavior changes, swallowing and breathing safety, caregiver support, and future care can help protect comfort, dignity, and independence.

Living with a diagnosis of ATP13A2-related disease means preparing for a journey that is progressive and unique to every individual. While the condition is lifelong and the symptoms will change over time, many families find that proactive planning and a focus on quality of life help them navigate the challenges ahead [1][2].

Navigating Physical Changes

The long-term outlook for mobility varies depending on whether the disease follows the Kufor-Rakeb (parkinsonism) or SPG78 (spasticity) pattern.

  • Gait and Balance: Most people will experience a gradual change in how they walk. This may be due to bradykinesia (slowness), spasticity (stiffness), or ataxia (lack of coordination) [3][1].
  • Mobility Transitions: Many patients eventually transition to using mobility aids. Natural history data are based on small reports, so the rate of progression and long-term mobility outcomes vary widely and cannot be reliably predicted from a published average [4]. However, others with more aggressive forms may require a wheelchair sooner to prevent falls and maintain independence [5]. Fall-proofing the home, adjusting work or school accommodations, and seeking occupational therapy early can preserve independence safely.
  • Energy Conservation: As movement becomes more effortful, learning “energy conservation” techniques—such as scheduling demanding tasks for times when medications are most effective—can help maintain daily activity [6].

Managing Cognitive and Emotional Well-being

Cognitive decline and psychiatric changes are a recognized part of the long-term clinical spectrum [7].

  • Cognitive Support: Decline can range from mild forgetfulness to more significant dementia [3]. Using calendars, routine schedules, and simplified environments can help manage these changes.
  • Psychiatric Stability: Behavioral outbursts or psychosis (hallucinations) may emerge as the disease progresses [8][9]. Early intervention with a neuropsychiatrist is key to keeping these symptoms from impacting the person’s safety or quality of life [8].

Safeguarding Nutrition and Breathing

As the muscles used for speaking and swallowing are affected, two major long-term health priorities emerge:

  1. Swallowing Safety: Difficulty swallowing (dysphagia) can lead to aspiration, where food or liquid enters the lungs [10]. Never change liquid consistencies or diet independently, as thickeners can reduce fluid intake and cause dehydration without guaranteeing the prevention of pneumonia. Interventions like upright positioning, supervision, specific oral care, and following an individualized swallowing plan from a Speech-Language Pathologist are key [11][10].
  2. Respiratory Health: In rare cases where the disease affects the muscles used for breathing, your medical team may recommend monitoring of lung function based on symptoms. Report red flags like breathlessness, weak cough, morning headaches, recurrent chest infections, or excessive daytime sleepiness promptly [12].

The Caregiver’s Journey

Because ATP13A2-related disease is a “family diagnosis,” caregiver support is not optional—it is a medical necessity. The increasing need for daily assistance, supervision for safety, and the emotional toll of cognitive changes can lead to significant burnout [8][13].

  • Respite Care: Seeking help from professional caregivers or family members for even a few hours a week can provide essential rest.
  • Future Planning: Engaging in “advanced care planning”—discussing medical wishes and financial/legal arrangements—while the patient can still participate fully in the conversation provides peace of mind for the entire family. Plan for long-term needs, such as driving assessments, managing the swallowing of medications, and eventual discussions about nutrition support (like a feeding tube) if swallowing becomes unsafe.
  • Community: Connecting with rare disease organizations (like those for NCL or NBIA) can reduce the isolation that often comes with an ultra-rare diagnosis.

While the disease is progressive, the goal of modern medical care is to ensure that every stage of life is lived with as much comfort, dignity, and connection as possible [2][14].

Common questions in this guide

What is the long-term outlook for ATP13A2-related disease?
ATP13A2-related disease is progressive, but the rate and pattern of change vary widely. Walking, balance, thinking, behavior, swallowing, and sometimes breathing may become more difficult over time. Studies involving small numbers of people cannot reliably predict how quickly one person will need mobility aids or other support.
When should we consider a cane, walker, or wheelchair?
Mobility aids may become useful as gait, balance, or coordination worsen, both to prevent falls and to preserve independence. Timing is individual, and more aggressive disease can require a wheelchair sooner. An occupational therapist and the medical team can help assess safe equipment and home changes.
How should swallowing problems be managed in CLN12 disease?
Swallowing difficulty can allow food or liquid to enter the lungs and raise the risk of aspiration and pneumonia. Follow an individualized plan from a speech-language pathologist, including upright positioning, supervision when needed, and careful mouth care. Do not change liquid thickness or diet on your own because thickeners may reduce fluid intake and do not guarantee prevention of pneumonia.
Which breathing changes should be reported to the medical team?
Report breathlessness, a weak cough, morning headaches, repeated chest infections, or unusual daytime sleepiness promptly. These signs may indicate that breathing muscles or breathing during sleep need evaluation. The medical team may recommend lung-function monitoring based on symptoms.
How can cognitive or behavioral changes be supported?
Forgetfulness, dementia, outbursts, or hallucinations can occur as ATP13A2-related disease progresses. Calendars, regular routines, and a simpler environment may help with memory and daily safety. Early input from a neuropsychiatrist can help address behavioral changes or hallucinations.
What can caregivers do to prepare for the future?
Caregivers can arrange regular respite, connect with rare-disease support groups, and discuss future wishes while the person's thinking is stable. Advance care planning can cover medical decisions, legal and financial arrangements, driving, medication swallowing, and possible nutrition support if swallowing becomes unsafe. A palliative care clinician can help address comfort and long-term needs.

Get notified when new evidence is published on CLN12 disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Motor Neuron Involvement in Two ATP13A2-Related Families: ALS And HSP-Like Phenotypes.

    Khosravi S, Amini E, Emamikhah M, et al.

    Movement disorders clinical practice 2025; (12(6)):852-857 doi:10.1002/mdc3.70027.

    PMID: 40028680
  2. 2

    Kufor-Rakeb Syndrome in a Guatemalan Patient With an ATP13A2 Gene Pathogenic Variant: A Case Report.

    Méndez-Veras R, Urbizo A, Cabrera J, Boburg S

    Case reports in genetics 2025; (2025()):6993134 doi:10.1155/crig/6993134.

    PMID: 41306646
  3. 3

    Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

    Estrada-Cuzcano A, Martin S, Chamova T, et al.

    Brain : a journal of neurology 2017; (140(2)):287-305 doi:10.1093/brain/aww307.

    PMID: 28137957
  4. 4

    Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders.

    Amini E, Rohani M, Lang AE, et al.

    Movement disorders clinical practice 2024; (11(1)):53-62 doi:10.1002/mdc3.13933.

    PMID: 38291840
  5. 5

    A novel ATP13A2 variant causing complicated hereditary spastic paraplegia.

    Zhang F, Liu P, Li J, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(4)):1749-1753 doi:10.1007/s10072-024-07334-w.

    PMID: 38252374
  6. 6

    French guidelines for the diagnosis and management of pure hereditary spastic paraplegia.

    Mania-Pâris L, Ewenczyk C, Nicolas G, et al.

    Revue neurologique 2025; (181(6)):471-482 doi:10.1016/j.neurol.2025.05.001.

    PMID: 40450402
  7. 7

    Case Report: Novel ATP13A2 pathogenic variants associated with early-onset parkinsonism and a mini-review.

    Affronte L, Pini A, Pizzoli C, et al.

    Frontiers in genetics 2025; (16()):1588812 doi:10.3389/fgene.2025.1588812.

    PMID: 40799219
  8. 8

    Psychiatric Manifestations of ATP13A2 Mutations.

    Balint B, Damasio J, Magrinelli F, et al.

    Movement disorders clinical practice 2020; (7(7)):838-841 doi:10.1002/mdc3.13034.

    PMID: 33033738
  9. 9

    Successful treatment of psychosis in a patient with Kufor-Rakeb syndrome with low dose aripiprazole: a case report.

    McNeil-Gauthier AL, Brais B, Rouleau G, et al.

    Neurocase 2019; (25(3-4)):133-137 doi:10.1080/13554794.2019.1625928.

    PMID: 31232173
  10. 10

    Aspiration and silent aspiration in Niemann-Pick disease type C1: longitudinal findings from the NIH natural history study.

    Solomon BI, Munoz AM, Borruso A, et al.

    Orphanet journal of rare diseases 2026; (21(1)).

    PMID: 42693440
  11. 11

    Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.

    Pietrzak A, Badura-Stronka M, Kangas-Kontio T, et al.

    Folia neuropathologica 2019; (57(3)):285-294 doi:10.5114/fn.2019.88459.

    PMID: 31588715
  12. 12

    Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion.

    Spataro R, Kousi M, Farhan SMK, et al.

    Human genomics 2019; (13(1)):19 doi:10.1186/s40246-019-0203-9.

    PMID: 30992063
  13. 13

    Action Myoclonus and Seizure in Kufor-Rakeb Syndrome.

    Rohani M, Lang AE, Sina F, et al.

    Movement disorders clinical practice 2018; (5(2)):195-199 doi:10.1002/mdc3.12570.

    PMID: 30868101
  14. 14

    Pallidal degenerations and related disorders: an update.

    Jellinger KA

    Journal of neural transmission (Vienna, Austria : 1996) 2022; (129(5-6)):521-543 doi:10.1007/s00702-021-02392-2.

    PMID: 34363531

This page is for informational purposes only and does not constitute medical advice. Your neurology and supportive-care teams can tailor mobility, swallowing, breathing, and future-planning recommendations to your situation.